Moderna doubles down on rare diseases; FDA advisory committee votes on fall Covid campaign; Illumina CEO steps down; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

As a re­minder, the End­points team will be off on Mon­day. We’ll be back in your in­box on Tues­day, and keep an eye out for our vir­tu­al cov­er­age of the 2023 Cannes Li­ons In­ter­na­tion­al Fes­ti­val of Cre­ativ­i­ty. Phar­ma ad­ver­tis­ing award sub­mis­sions surged al­most 20% this year, and we’ll tell you all you need to know about this year’s win­ners. — Nicole De­Feud­is

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN